Literature DB >> 25957167

Generation of TCR-engineered T cells and their use to control the performance of T cell assays.

Nicole Bidmon1, Sebastian Attig2, Richard Rae1, Helene Schröder1, Tana A Omokoko1, Petra Simon1, Andreas N Kuhn1, Sebastian Kreiter1, Ugur Sahin2, Cécile Gouttefangeas3, Sjoerd H van der Burg4, Cedrik M Britten5.   

Abstract

The systematic assessment of the human immune system bears huge potential to guide rational development of novel immunotherapies and clinical decision making. Multiple assays to monitor the quantity, phenotype, and function of Ag-specific T cells are commonly used to unravel patients' immune signatures in various disease settings and during therapeutic interventions. When compared with tests measuring soluble analytes, cellular immune assays have a higher variation, which is a major technical factor limiting their broad adoption in clinical immunology. The key solution may arise from continuous control of assay performance using TCR-engineered reference samples. We developed a simple, stable, robust, and scalable technology to generate reference samples that contain defined numbers of functional Ag-specific T cells. First, we show that RNA-engineered lymphocytes, equipped with selected TCRs, can repetitively deliver functional readouts of a controlled size across multiple assay platforms. We further describe a concept for the application of TCR-engineered reference samples to keep assay performance within or across institutions under tight control. Finally, we provide evidence that these novel control reagents can sensitively detect assay variation resulting from typical sources of error, such as low cell quality, loss of reagent stability, suboptimal hardware settings, or inaccurate gating.
Copyright © 2015 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25957167     DOI: 10.4049/jimmunol.1400958

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  3 in total

Review 1.  Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation.

Authors:  Giuseppe V Masucci; Alessandra Cesano; Rachael Hawtin; Sylvia Janetzki; Jenny Zhang; Ilan Kirsch; Kevin K Dobbin; John Alvarez; Paul B Robbins; Senthamil R Selvan; Howard Z Streicher; Lisa H Butterfield; Magdalena Thurin
Journal:  J Immunother Cancer       Date:  2016-11-15       Impact factor: 13.751

2.  PLGA Nanoparticles Co-encapsulating NY-ESO-1 Peptides and IMM60 Induce Robust CD8 and CD4 T Cell and B Cell Responses.

Authors:  Yusuf Dölen; Uzi Gileadi; Ji-Li Chen; Michael Valente; Jeroen H A Creemers; Eric A W Van Dinther; N Koen van Riessen; Eliezer Jäger; Martin Hruby; Vincenzo Cerundolo; Mustafa Diken; Carl G Figdor; I Jolanda M de Vries
Journal:  Front Immunol       Date:  2021-02-25       Impact factor: 7.561

3.  A framework for T cell assays.

Authors:  Cedrik M Britten; Sjoerd H van der Burg; Cécile Gouttefangeas
Journal:  Oncotarget       Date:  2015-11-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.